Acura Pharmaceuticals, Inc. · OTC:ACUR

Acura Pharmaceuticals — Investor Presentation (March 2016)

19 slides from Acura Pharmaceuticals's investor presentation, Mar 11, 2016

  1. Slide 1: Abuse Deterrent Specialty Pharmaceuticals

    CONFIDENTIAL Nasdaq: ACUR March 2016 Abuse Deterrent Specialty Pharmaceuticals

  2. Slide 2: General Caution Regarding Forward Looking Statements

    Nasdaq: ACUR General Caution Regarding Forward Looking Statements Certain statements in this presentation constitute “forward - looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 . Such forwarding - looking statements involve known and unknown risks, uncer

  3. Slide 3: Abuse of Prescription Opioids

    Nasdaq: ACUR Abuse of Prescription Opioids Opioid Analgesics Morphine Hydrocodone (Vicodin®) Oxycodone (Percocet®, OxyContin®) etc. Moderate to Severe Pain US’s largest prescribed drug category Acute vs Chronic Immediate vs Extended Release Euphoria Over Ingestion Snorting Injection Tolerance, Depen

  4. Slide 4: FDA Incentivizes Oral Abuse Deterrence in Immediate-release Formulations

    Nasdaq: ACUR FDA Incentivizes Oral Abuse Deterrence in Immediate - release Formulations • April 2015 – FDA Guidance “Abuse Deterrent Opioid – Evaluation and Labeling” • Immediate - release opioids containing acetaminophen (APAP) • Predominately abused by the oral route • Addressing nasal abuse may n

  5. Slide 5: Acura's Abuse Deterrent Technology Platforms

    Nasdaq: ACUR Acura’s Abuse Deterrent Technology Platforms - Opioid Abuse – Oral, Snorting and Injection - Accidental overdose of NTI drugs - Immediate - Release Segment - $ 2.9 billion addressable segment with pricing leverage - Partnership Opportunities - Issued US Patent to 2033 - Pseudoephedrine

  6. Slide 6: The Limitx Technology

    Nasdaq: ACUR Illustration The Limitx™ Technology Product Formulation • Micro - particles containing the opioid active ingredient • Functional tablet matrix of other ingredients Oral Abuse Deterrence • Tablet matrix acts synergistically with the micro - particle ingredients to retard the release of m

  7. Slide 7: LTX-04 (hydromorphone) Tablet Dissolution

    Nasdaq: ACUR 7 LTX - 04 (hydromorphone) Tablet Dissolution LTX - 04 research is funded in part by a grant from NIDA who are not responsible for any research or results

  8. Slide 8: Study AP-LTX-400

    Nasdaq: ACUR Study AP - LTX - 400 Objective: Demonstrate therapeutic and safe blood levels for LTX - 04 at 1 and/or 2 tabs and diminishing marginal blood absorption ( Cmax and/or AUC) at 3+ tabs Cohort 1 – efficacious dose levels • 30 subjects enrolled to target 24 completers • 1, 2 and 3 tablet sub

  9. Slide 9: Limitx Benefits

    Nasdaq: ACUR Limitx™ Benefits Nasdaq: ACUR As identified by o pioid prescribers 9 Source: Company Research, 8 physicians

  10. Slide 10: Immediate Release Opioids Market Opportunity

    Nasdaq: ACUR Immediate Release Opioids Market Opportunity 2014 Addressable Market (millions) Immediate - release Opioid Reference Brand(s) TRx Tablets Dollars Price/ Tab* Hydrocodone/APAP Vicodin, Norco 117.5 6,883 984 .14 Oxycodone/APAP Percocet 35.5 2,206 994 .45 Oxycodone Roxicodone 14.8 1,672 48

  11. Slide 11: Limitx Near Term Activities

    Nasdaq: ACUR Limitx™ Near Term Activities • 1H - 2016 • Announce topline pilot pharmacokinetic study (AP - LTX - 400) results • Potential to announce interim results • Complete formulation LTX - 03 (Hydrocodone/APAP) • Evaluate Partnering Opportunities • 2H - 2016 • Hold “End of Phase 2” meeting wit

  12. Slide 12: Marketed Product Opportunities

    Nasdaq: ACUR Marketed Product Opportunities • Aversion® Opioids Analgesic • Oxaydo ™ FDA approved • Licensed worldwide to Egalet Corp. • Product launched in the US in September 2015 • Supported by 50 sales representatives • Differentiated abuse deterrent label (snorting) • 1.7 billion tablet address

  13. Slide 13: Oxaydo - Egalet Partnership

    Nasdaq: ACUR • Egalet has US and EU Operations • Extended - release abuse deterrent formulations in development • Right of first negotiation for a Limitx™ oxycodone product Financial Terms • $5.0 million upfront payment • $2.5 million upon first US product shipment • $ 12.5 million one time mileston

  14. Slide 14: Impede Technology/Nexafed Franchise

    Nasdaq: ACUR Impede® Technology/Nexafed® Franchise • Chemical conversion of pseudoephedrine (PSE) from cold products into methamphetamine • Dangerous, toxic process requires costly clean - up and creates child endangerment • Highly addictive – no pharmaceutical treatment • 1.2 million people in the

  15. Slide 15: Impede - Expansion/Partnering Opportunities

    Nasdaq: ACUR $0 $20 $40 $60 $80 2014 US ex - Factory 1 Sales ($340 Million) PSE/Cetirizine* PSE/ Loratadine * PSE 30mg PSE 120mg* PSE/Ibuprofen PSE/fexofenadine* Impede® - Expansion/Partnering Opportunities *12 Hour Extended - Release • Higher value targets in extended - release segment • Move to be

  16. Slide 16: Intellectual Property

    Nasdaq: ACUR Intellectual Property 16

  17. Slide 17: Intellectual Property Position

    Nasdaq: ACUR • Limitx™ Technology: U.S. issued patent expires 2033 • 1 U.S. patent issued • 1 Canadian notice of allowance • Aversion® Technology: U.S. issued patents expire 2023 to 2025 • 6 U.S. patents issued • US Generic market entry January 2022 • Patents issued in selected foreign jurisdictions

  18. Slide 18: Expectations for 2016

    Nasdaq: ACUR • Sufficient cash to execute current business plan through 2016 • Limitx™ Technology • Final Topline results from Study AP - LTX - 400 in 1H 2016 • If successful, FDA End of phase 2 meeting on LTX - 04 and outline development program and timelines to NDA • Initial LTX - 03 Formulation a

  19. Slide 19: Acura Pharmaceuticals, Inc.

    CONFIDENTIAL Nasdaq: ACUR Acura Pharmaceuticals, Inc. 616 N. North Court, Suite 120 Palatine, IL 60067 (847) 705 - 7709 www.AcuraPharm.com www.Nexafed.com www.Oxaydo.com

Acura Pharmaceuticals — Investor Presentation (March 2016) on 6ix